{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:30:48Z","timestamp":1760383848033,"version":"3.41.2"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2001,8,1]],"date-time":"2001-08-01T00:00:00Z","timestamp":996624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,8,1]],"date-time":"2001-08-01T00:00:00Z","timestamp":996624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2001,8]]},"DOI":"10.1023\/a:1010624702340","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T22:31:49Z","timestamp":1040596309000},"page":"239-243","source":"Crossref","is-referenced-by-count":4,"title":["Phase II Trial of CI-980 in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy \u2013 A Southwest Oncology Group Study"],"prefix":"10.1007","volume":"19","author":[{"given":"Robert P.","family":"Whitehead","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence E.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukund S.","family":"Didolkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfram","family":"Samlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vernon K.","family":"Sondak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"338103_CR1","volume-title":"Cancer: Principles and Practice of Oncology","author":"CM Balch","year":"1997","unstructured":"Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, Ang KK: Cutaneous Melanoma. Ch. 41.2. In: DeVita VT Jr, Hellman S, Rosenberg SA (Eds) Cancer: Principles and Practice of Oncology. 5th Edn. Lippincott-Raven Publishers, Philadelphia, 1997","edition":"5th Edn."},{"key":"338103_CR2","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","volume":"17","author":"PB Chapman","year":"1999","unstructured":"Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwalla SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM: Phase III multicenter randomized trial of the Dartmouth Regimen versus Dacarbazine in patients with metastatic melanoma. J Clin Oncol 17: 2745\u20132751, 1999","journal-title":"J Clin Oncol"},{"key":"338103_CR3","first-page":"791","volume":"42","author":"GP Wheeler","year":"1982","unstructured":"Wheeler GP, Bowdon BJ, Werline JA, Adamson DJ, Temple CG: Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,2-dihydro-3-[(N243 methylanilino)methyl]-pyridol [3,4-b] pyrazin-7-ylcarbamate (NSC 181928). Cancer Res 42: 791\u2013798, 1982","journal-title":"Cancer Res"},{"key":"338103_CR4","first-page":"3567","volume":"43","author":"GP Wheeler","year":"1983","unstructured":"Wheeler GP, Bowdon BJ, Temple C Jr, Adamson DJ, Webster J: Biological effects and structure \u2013 activity relationships of 1,2-dihydropyrido [3,4-b] pyrazines. Cancer Res 43: 3567\u20133575, 1983","journal-title":"Cancer Res"},{"key":"338103_CR5","first-page":"1621","volume":"47","author":"BJ Bowdon","year":"1987","unstructured":"Bowdon BJ, Waud WR, Wheeler GP, Hain RH, Dansby L, Temple CG: Comparison of 1,2-dihydropyrido [3,4-b] pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis. Cancer Res 47: 1621\u20131626, 1987","journal-title":"Cancer Res"},{"key":"338103_CR6","unstructured":"Park-Davis Pharmaceutical Research Division, Warner-Lambert Company, Investigator's Brochure, 1990"},{"key":"338103_CR7","first-page":"3239","volume":"50","author":"WR Waud","year":"1990","unstructured":"Waud WR, Leopold WR, Elliot WL, Dykes DJ, Laster WR Jr, Temple CG Jr, Harrison SD Jr, Griswold DP Jr: Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyridol [3,4-b] pyrazin-7-ylcarbamate, 2 hydroxyethanesulfonate hydrate (NSC 370147) against selected tumor systems in culture and in mice. Cancer Res 50: 3239\u20133244, 1990","journal-title":"Cancer Res"},{"key":"338103_CR8","first-page":"306","volume":"27","author":"DP Griswold Jr","year":"1986","unstructured":"Griswold DP Jr, Temple CG Jr, Trader MW, Leopold WR III, Laster WR Jr, Dykes DJ: Antitumor activity of novel 1,2-dihydropyrido [3,4-b]-pyrazine in preclinical drug-sensitive and resistant tumors. Proc Am Ass Cancer Res 27: 306, 1986","journal-title":"Proc Am Ass Cancer Res"},{"key":"338103_CR9","first-page":"401","volume":"3","author":"EK Rowinsky","year":"1997","unstructured":"Rowinsky EK, Long GS, Noe DA, Grochow LB, Bowling MK, Sartorius SE, Donehower RC: Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Clin Cancer Res 3: 401\u2013407 1997","journal-title":"Clin Cancer Res"},{"key":"338103_CR10","first-page":"75","volume":"54","author":"C de Ines","year":"1994","unstructured":"de Ines C, Leynadier D, Barasoain I, Peyrot V, Garcia P, Briand C, Rener GA, Temple C Jr: Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863. Cancer Res 54: 75\u201384, 1994","journal-title":"Cancer Res"},{"key":"338103_CR11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00000421-199712000-00008","volume":"20","author":"R Pazdur","year":"1997","unstructured":"Pazdur R, Meyers C, Diaz-Canton E, Abbruzzese JL, Patt Y, Grove W, Ajani J: Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. Am J Clin Oncol 20: 573\u2013576, 1997","journal-title":"Am J Clin Oncol"},{"key":"338103_CR12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1006078930550","volume":"16","author":"SR Patel","year":"1998","unstructured":"Patel SR, Burgess MA, Papadopolous NE, Sidhu G, Gray R, Plager C, Jenkins J, Benjamin RS: Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. Invest New Drugs 16: 87\u201392, 1998","journal-title":"Invest New Drugs"},{"key":"338103_CR13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00001813-199806000-00006","volume":"9","author":"AP Kudelka","year":"1998","unstructured":"Kudelka AP, Hasenburg A, Verschraegen CF, Edwards CL, Meyers CA, Varma D, Freedman RS, Forman A, Conrad CA, Grove W, Grothey A, Kavanagh JJ: Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anti-Cancer Drugs 9: 405\u2013409, 1998","journal-title":"Anti-Cancer Drugs"},{"key":"338103_CR14","first-page":"296","volume":"34","author":"WR Leopold","year":"1993","unstructured":"Leopold WR, Elliott WL, Pryzbranowski SA, Waud WR: In vivo evaluation of the potential for therapeutic synergy between CI-980 and standard chemotherapeutic agents. Proceedings AACR 34: 296, 1993 (abstract)","journal-title":"Proceedings AACR"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1010624702340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1010624702340\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1010624702340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:56:30Z","timestamp":1753818990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1010624702340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["338103"],"URL":"https:\/\/doi.org\/10.1023\/a:1010624702340","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2001,8]]}}}